- Partnership provides worldwide commercial license and supply agreement for enterade®, an amino acid-based, glucose-free, electrolyte solution designed for oncology and gastrointestinal disease patients -

NORWOOD, Mass. /PRNewswire/ -- Entrinsic Health Solutions (EHS), an innovative health sciences company, today announced that they have entered into a partnership with Nestlé Health Science (NHSc), a global innovative leader pioneering premium-quality, science-based nutritional health solutions. The partnership gives NHSc the exclusive rights to market EHS's enterade® product.

This partnership is structured as a worldwide commercial license and supply agreement for EHS's electrolyte beverage using a patented combination of proprietary amino acids to help address hydration issues in patients with gastrointestinal (GI) issues related to cancer or chronic GI disease. NHSc has the right to take over the global commercialization of enterade® following the results of the clinical study of enterade® in neuroendocrine tumor (NET) patients. Terms of the transaction have not been disclosed.

"We are excited to partner with Nestlé Health Science, a leader in nutritional health solutions that empower healthier lives. This partnership underscores our commitment to providing disruptive, science-derived products utilizing our Amino Acid Coupled-Transport (A₂CT™) technology platform to deliver better health outcomes in a broad range of therapeutic areas for patients in need of better nutritional support options. enterade® was designed to address the specific hydration needs of those patients undergoing cancer treatment or those with chronic GI impairment. We look forward to a long-term and productive relationship with Nestlé Health Science," said Stephen J. Gatto, Chairman and CEO of EHS.

Greg Behar, CEO of Nestlé Health Science, stated: "We are pleased to collaborate with Entrinsic Health Solutions. enterade®'s proprietary blend of scientifically-selected amino acids and electrolytes uniquely addresses the hydration needs of patients with cancer and chronic GI disease. Clinical studies and in-market patient experience confirm the efficacy and benefits that enterade® offers these patient groups. This partnership underscores our commitment to leading-edge innovation and to providing a comprehensive range of science-based, nutritional health solutions that enable consumers and patients to live healthier lives."

A prospective Phase II study of enterade® in NET and carcinoid syndrome patients with quality-of-life limiting diarrhea has been initiated and is expected to conclude in 2019. This new study will assess how enterade® helps patients absorb and retain fluids. A pilot clinical study conducted at the University of Kentucky Markey Cancer Center demonstrated that daily consumption of enterade® leads to a marked improvement in patient's overall quality of life. These results were published in the 2018 ASCO Annual Meeting Proceedings.


Contact Entrinsic Health Solutions:
Stephen Gatto

Chief Executive Officer
781-352-5459

SOURCE Entrinsic Health Solutions, Inc.